ReviewNature reviews. Clinical oncology2011
Beyond chemotherapy: new agents for targeted treatment of lymphoma.
Review in Nature reviews. Clinical oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.Blood · 2012Trial
- Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.The Lancet. Oncology · 2011Trial
- UMG1 Defines a Targetable Subset of T-Cell Lymphomas and Enables Precision Immunotherapy With a First-in-Class CD3ε Bispecific Engager.Hematological oncology · 2026Article
- The antitumor mechanism of oclacitinib in canine lymphoma.Scientific reports · 2026Article
- Mantle cell lymphoma polarizes tumor-associated macrophages into M2-like macrophages, which in turn promote tumorigenesis.Blood advances · 2021Article
- Extracellular Vesicles: New Players in Lymphomas.International journal of molecular sciences · 2018Review
- Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies.Chronic diseases and translational medicine · 2018Review
- Protease nexin-1 prevents growth of human B cell lymphoma via inhibition of sonic hedgehog signaling.Blood cancer journal · 2018Article
- Article
- JAK1/2 Inhibitors AZD1480 and CYT387 Inhibit Canine B-Cell Lymphoma Growth by Increasing Apoptosis and Disrupting Cell Proliferation.Journal of veterinary internal medicine · 2017Article
- The landscape of new drugs in lymphoma.Nature reviews. Clinical oncology · 2017Review
- Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies.Critical reviews in oncogenesis · 2017Review
- The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest.Leukemia · 2016Article
- Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation.Scientific reports · 2016Article
- The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Article
- Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas.Leukemia & lymphoma · 2016Article
- Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies.Oncology letters · 2015Article
- Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?Bone marrow transplantation · 2015Review
- Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.The oncologist · 2015Article
- Inhibition of methyltransferases accelerates degradation of cFLIP and sensitizes B-cell lymphoma cells to TRAIL-induced apoptosis.PloS one · 2015Article
Corrections and comments
- Erratum issued
Authors and funding
1 author.
Funding
Abstract
An improved understanding of the molecular biology of cancer cell growth and survival and the role of the microenvironment in supporting the survival of cancer cells, including lymphoma cells, has led to the identification of a number of potential therapeutic targets. Despite these advances, drug development for lymphoma remains slow, inefficient, and frequently unfocused. Future work should focus on identifying 'driver' molecular defects of oncogenic pathways that can be targeted therapeutically, discovering predictive biomarkers for treatment response, and prioritizing promising drugs to accelerate their approval. This Review summarizes the current development status of novel agents for lymphoma and discusses strategies to move the field forward.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.